Document:

EX-10.8

 Exhibit 10.8 

DISTRIBUTION AGREEMENT 

This DISTRIBUTION AGREEMENT (the “Agreement”), by and between AMEDICA CORPORATION, a Delaware corporation with a
principal place of business at 1885 West 2100 South, Salt Lake, City, Utah 84119 (“Amedica”) and Orthopaedic Synergy, Inc., a Delaware corporation with a principal place of business at 50 O’Connell Way #10, East Taunton, MA 02718 (the
“OSI”) is effective as of the 22nd day of February, 2010 (the “Effective Date”). Amedica and OSI are each referred to herein as a “Party” and collectively as the
“Parties.” 
 W I T N E S S E T H 

WHEREAS, Amedica designs and manufactures implantable orthopedic medical products and devices to be marketed, sold and distributed
worldwide; 
 WHEREAS, certain of Amedica’s products are manufactured utilizing a material known as Silicon Nitride
(“SiN”) which material is known to have particularly unique properties with respect to strength, wear, and bone ingrowth; 

WHEREAS, OSI manufacturers, markets, and sells implantable medical devices, including total hip and knee systems and related
instrumentation; 
 WHEREAS, OSI wishes to use certain of Amedica’s SiN components in the manufacture of certain of OSI’s
total implant systems; and 
 WHEREAS, Amedica desires to provide OSI with SiN components as more fully described herein pursuant to
the terms and conditions of this Agreement. 
 NOW THEREFORE, in consideration of the mutual agreements hereinafter set forth, the
Parties agree as follows: 
 1. DEFINITIONS. For the purpose of this Agreement, the following definitions will apply: 

a. “Product” or “Products” means Amedica’s SiN femoral head component in sizes to be determined by the Parties. 

b. “Territory” means all [***]. 

c. “OSI Hip System” means the total hip system into which the Products will be incorporated and which OSI will sell in the
Territory. 
 2. UNDERTAKINGS OF AMEDICA. Amedica agrees as follows: 

a. Product Supply. Amedica shall make [***] to supply OSI with quantities and sizes of the Products as requested by OSI pursuant to
written purchase orders. Purchase orders shall not be binding until accepted by Amedica and Amedica shall notify OSI promptly in the event that it rejects any purchase order. 

b. [***]. [***]. 
 c. Certain
Technical Information. Amedica will inform OSI in the event of any changes in indications, applications and/or contraindications or any recalls or restrictions of usage issued by any regulatory agency and applicable to any of the Products. 

 d. Insurance. Amedica shall maintain products liability and other insurance in such
amounts [***]. 
 3. UNDERTAKINGS OF OSI. OSI agrees to: 

a. vigorously promote within the Territory the distribution and sale of the OSI Hip System in a manner that [***]; 

b. assist Amedica as may be needed from time to time to comply with all applicable laws and regulations regarding the tracking and
traceability of products and any other local applicable regulations in each and every jurisdiction where OSI sells the Products; and, comply with and keep Amedica timely advised with respect to all laws, licensing regulations and rulings of
governmental bodies having jurisdiction over OSI’s business concerning the sale of the Products; 
 c. exercise all necessary care in
storing the Products to insure their merchantability as safe and effective products, and maintain errors and omissions, general liability and all risk insurance in such amounts as are reasonably acceptable to Amedica and provide proof of such
insurance to Amedica upon request; 
 d. advise Amedica of any suit, claim, complaint or performance issues known to OSI resulting from the
sale or use of any of the Products, as well as any recalls or restrictions of usage issued by a regulatory agency; 
 e. provide samples of
all marketing and promotional materials which relate in any way to the Products to Amedica for Amedica’s prior approval, which approval shall not be unreasonably withheld; 

4. TERM AND TERMINATION. 
 a.
Subject to the termination rights contained in this Agreement, the initial term of this Agreement shall be for period of five (5) years commencing on the Effective Date. Thereafter, the Parties may agree to extend the Agreement provided such
agreement is committed to writing and signed by authorized representatives of both Parties. 
 b. This Agreement may be terminated for any
of the following reasons: 
 (i) by either Party in the event that the other party breaches this Agreement and fails to cure such breach
within thirty (30) days of its receipt of written notice from the non-breaching Party specifying the details of such breach; 
 (ii) by
Amedica in the event that OSI fails to exercise reasonable best efforts in the distribution and sale of the Products pursuant to this Agreement; 

(iii) either Party, by written notice to the other, may terminate this Agreement immediately if either Amedica or OSI (as applicable):
(A) [***] its business, (B) becomes subject to any bankruptcy or insolvency proceeding under federal or state law, (C) becomes insolvent or becomes subject to direct control by a trustee, receiver or similar authority, or (D) has
wound up or liquidated its business voluntarily or otherwise; 

  
 2 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (iv) immediately by either Party if the other Party intentionally engages in wrongful acts which
materially impair the goodwill or business of Amedica or cause material damage to Amedica’s property, goodwill, or business; and 
 (v)
immediately by either Party and upon written notice to the other in the event that a Party (or any of a Party’s members, shareholders, directors, managers, employees or agents) is excluded from, debarred or otherwise subject to sanctions by the
Medicare or Medicaid programs or is assessed any civil or criminal fines or penalties under such programs or under federal or state anti-kickback or Stark laws. 

c. Any termination of this Agreement shall constitute a cancellation of all orders from OSI, whether received prior to or after such
termination, but shall [***] which OSI may then have with Amedica; provided however, that after termination of this Agreement, OSI shall have the right to distribute and/or sell Products [***] or [***] until such products [***] or [***], whichever
occurs first. Upon any such termination of this Agreement, Amedica shall [***] in any manner whatsoever on account of such [***]; furthermore, Amedica shall not, for any reason whatsoever, including but not limited to the breach, termination,
cancellation or expiration of this Agreement, [***],[***], either on account of [***] or on account of any other thing or cause whatsoever, including, without limitation, [***], whether arising out of warranty or other contract, negligence or other
tort, or otherwise. 
 5. INTELLECTUAL PROPERTY RIGHTS; COMPETING PRODUCTS; CONFIDENTIAL INFORMATION. The Parties agree that all trademarks,
copyrights, patents, trade secrets, service marks, trade dress and other intellectual property and/or proprietary rights of Amedica and/or associated with the Products (the “Intellectual Property Rights”) are the sole and exclusive
property of Amedica unless otherwise provided herein or in that certain Joint Development Agreement executed by the Parties and dated February 8, 2010. No action of Amedica or any provision in this Agreement shall, at any time, be deemed as
transferring any Intellectual Property Rights of Amedica to OSI or creating any other right in or to such Intellectual Property Rights in OSI. 
 6.
TERMS AND CONDITIONS. 
 a. Pricing and [***]. [***] shall [***]agree on pricing for the OSI Hip System into which
the Products are incorporated, which pricing shall depend upon all reasonable and customary factors including without limitation [***], availability of [***], etc. Individual component pricing for the Products shall be agreed upon between the
Parties prior to any sale to any third Party. All prices shall be committed to writing. The Parties shall [***] the [***] amount for each Product. [***] is defined as the [***] less (i) [***]; (ii) [***]; (iii) [***]; and
(iv) [***]. 
 b. Right to Audit. Either Party will have the right to audit all cost calculations upon reasonable notice
in writing to the other Party, however in no event shall such right to audit be exercised more than once per calendar year. In the event that an audit evidences that such costs have been figured incorrectly and to the detriment of the Party
requesting the audit, [***]. 
 c. Invoicing upon Shipment. Amedica shall invoice OSI [***] upon shipment of same to OSI.
Payment for all such invoices shall be [***] from the date on each invoice presented to OSI by Amedica. 

  
 3 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 d. Quarterly [***] Reconciliation. Within [***] of the end of each calendar
quarter, OSI shall provide to Amedica a reconciliation of the [***] sold during each such calendar quarter. Payment due Amedica as evidenced by each reconciliation report shall be included with each reconciliation forwarded to Amedica pursuant to
this Section 6(d). 
 e. Orders and Deliveries. All orders received by Amedica from OSI are subject to written acceptance
by Amedica. Amedica may reject any order which it receives from OSI. OSI shall provide shipping instructions to Amedica. 
 7. PRODUCT WARRANTIES AND
LIMITATIONS ON DAMAGES. OSI shall make no warranty or representation with respect to Amedica or any of the Products, whether express or implied, unless first approved by Amedica in writing, and in such case, provided that OSI shall be solely
responsible for any claims made under, or with respect to, any such warranty. Amedica will likewise make no warranty or representation with respect to OSI’s product offerings. 

8. PRODUCT IDENTIFICATION. All Products incorporated into the OSI Hip System and sold by OSI shall name Amedica as manufacturer of
the Products. 
 9. INDEMNITY. 

a. By Amedica. To the extent not otherwise covered by insurance, Amedica shall defend, indemnify and hold harmless OSI from and
against any liabilities, losses, damages, costs and expenses (including reasonable attorney fees and other costs and expenses) arising out of: (i) any claim or action brought against OSI for any claim that the Products infringe any United
States patent, copyright, trademark or trade secret under United States law, provided that, OSI promptly notifies Amedica in writing of such claim and allows Amedica to control, and fully cooperates with Amedica in, the defense of any such claim or
action and any settlement negotiations related thereto. Notwithstanding the above, Amedica shall have no liability for any settlement or compromise made without its express written consent. In the event of a claimed infringement, Amedica reserves
the right to do any of the following: replace the Product with a non-infringing product or a product of equivalent functionality; modify the Product to make it non-infringing; procure for OSI the right to continue using said Product; or remove the
Product and refund the price paid to Amedica for such Product. The foregoing constitutes Amedica’s entire liability in the event of any claim of intellectual property infringement. 

b. By OSI. OSI shall defend, indemnify and hold harmless Amedica from and against any claim, liabilities, losses, damages, costs
and expenses (including reasonable attorney fees and other costs and expenses) associated with any claim or action that arises out of or relates to: (i) any [***] of OSI or its employees, agents or other representatives; (ii) any claims
arising from the [***] by OSI or its employees, agents or other representatives; (ii) any [***] of OSI, or its employees, agents or other representatives, to [***] under this Agreement; (iii) any [***] that OSI, or its employees, agents or
other representatives, make to [***]; (iv) any claim arising out of any [***] by OSI or its employees, agents or other representatives (except to the extent caused by Amedica’s errors or omissions); or (v) any [***] from OSI or its
employees, agents or other representatives. 

  
 4 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 10. RECORD KEEPING; INSPECTION. OSI shall keep accurate, up-to-date records of all its transactions in purchasing and selling the Products, including, [***]. Such records shall be retained for at least a period of four (4) years following such record year,
which record retention requirement shall survive the termination of this Agreement. [***], Amedica (and/or its designated agent) shall have the right to visit and inspect the place of business of OSI and to inspect such books at OSI’s principal
place of business during normal business hours during the Term of this Agreement and for a period of [***] following the termination or expiration of this Agreement. 

11. MISCELLANEOUS. 
 a.
Entire Agreement and Modification. This Agreement and the exhibits attached hereto constitute the entire understanding between the parties with respect to the subject matter hereof and supersedes all prior contemporaneous discussions,
agreements or representations, written or oral, concerning the subject matter of this Agreement. No modification or amendment of this Agreement shall be binding unless in writing signed by both parties hereto. 

b. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware,
without regard to conflict of law provisions. 
 c. Waiver. No waiver of any provision of this Agreement shall be valid unless
the same is in writing and signed by the party against whom such waiver is to be enforced. No failure, neglect or delay by a party to enforce any provision of this Agreement shall at any time be deemed a waiver of any other provision of this
Agreement at such time or shall be deemed a waiver of such provision at any other time. Failure to enforce any provision of this Agreement, by either party, shall not be construed as a waiver of that provision. 

d. Notice. Any notice or communication required or permitted to be given under this Agreement shall be in writing and shall be
served on the Parties at the address of the recipient Party listed above or to such other address, as any Party may by written notice designate. Any notice or communication required, permitted or desired to be given by any provision of this
Agreement shall be sent either (i) by prepaid certified or registered mail, return receipt requested, in which case notice shall be deemed received three business days after deposit, postage prepaid in the United States Mail; (ii) by
nationally recognized overnight courier, in which case notice shall be deemed received one business day after deposit with such courier provided that such courier has written evidence of delivery to such Party’s address; or (iii) by
facsimile with appropriate electronic confirmation or receipt. 
 e. Surviving Provisions. The Parties expressly agree that
the provisions contained in Section 6 regarding Price and Revenue Sharing relative to the Products shall survive the expiration and/or earlier termination of this Agreement unless otherwise agreed by the Parties or in the event of a breach of
this Agreement by either Party. Additionally, the provisions of Section 5, 7, 6, 9, 10, and 11 shall survive the expiration of earlier termination of this Agreement. 

f. Assignment. This Agreement is non-transferable except as permitted in this paragraph. Either Party to this Agreement may
assign its interest under this Agreement to any entity controlling, controlled by or under common control with such Party or an entity which is succeeding to the entire business of Company; provided, however, that either Party must assign its rights
and obligations under this Agreement to any purchaser of all or substantially all of the assets of said Party, in which case the purchaser shall remain liable for all of such Party’s obligations hereunder. 

  
 5 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 g. Relationship of the Parties. Nothing in this Agreement is intended to create an
exclusive business relationship between the Parties except as set out herein, nor will this Agreement be deemed or construed to constitute or create between the Parties a partnership, joint venture, agency, or other legal business entity. 

h. Provision Rendered Invalid. If any provision of this Agreement is invalid, illegal or incapable of being enforced under any
rule of law or public policy, Amedica may terminate this Agreement forthwith or, at its option, continue the Agreement as so modified by law or policy. 

i. Force Majeure. If during the term of this Agreement an event of force majeure should prevent either party from fulfilling
contractual obligations, the party so affected shall be excused from any liability for non-performance during the period of such force majeure; provided however, if such force majeure continues for more than thirty [***] then either party may
terminate this Agreement. 
 j. Ability to Contract. The Parties represent and warrant to each other that they are not
prohibited from entering into this Agreement, selling the Products or otherwise conducting business with each other as contemplated herein, whether due to any contract to which either is a party, or other commitment or obligation binding on either
party. 
 k. Production. Nothing herein shall be deemed to require that Amedica continue the production of any Product.
Amedica shall not be liable for delays in delivery or failure to perform any obligation hereunder due to force majeure or any other cause beyond its control, including, but not limited to, vendor problems, labor disputes, acts of war or terrorism,
fire, delays in transportation or shortages of materials or transportation supplies. 
 l. Confidential Nature of Terms and
Provisions. The Parties acknowledge and agree that the terms and provisions of this Agreement are confidential in nature and not to be disseminated to any third party unless required by law, court order, or other legal mandate.
Notwithstanding the foregoing, the parties are free to reference the existence of the business relationships between them in press releases, company websites, and any other public forum provided that such information publicly disclosed be limited to
the fact that the parties have entered into an agreement and the products made the subject matter of that agreement. 
 m. Multiple
Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original instrument, but both such counterparts together shall constitute but one agreement. 

n. Compliance with Laws and Regulations. The Parties represent and warrant that they: (i) will not violate or cause the
other Party to violate any provision of United States law; (ii) shall comply at all times with all worldwide applicable laws, including, without limitation, those related to medical devices, health care fraud and abuse and all federal and state
health care reimbursement programs, advertising, warranties, environmental concerns, national security, registration of commercial representatives, and employment; (iii) shall comply with the regulatory requirements of each jurisdiction in
which the Products are sold, to the extent that the same apply to the parties’ respective obligations under this Agreement. 

  
 6 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 NOW THEREFORE, the undersigned have executed this Agreement as of the Effective Date. 

 

			
	AMEDICA CORPORATION
	
	 /s/ Ben R. Shappley

	Ben R. Shappley, CEO
	
	ORTHOPAEDIC SYNERGY, INC.
		
	Its:	 	  

	
	  

  
 7 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 FIRST AMENDMENT AND ADDENDUM 

TO DISTRIBUTION AGREEMENT 
  

					
	DATED:	 	To be Effective as of November 1, 2012 (the “Amendment Date”).
		
	PARTIES:	 	The Parties, each individually a “Party”, to this First Amendment and Addendum to Distribution Agreement (herein the “First Amendment”) are:
			
		 	(a)	  	Orthopeadic Synergy Inc., a Delaware corporation (“OSI”);
			
		 	(b)	  	Amedica Corporation, (“Amedica”). OSI and Amedica are collectively referred to as the “Parties.”

 RECITALS 

OSI and Amedica entered into that certain Distribution Agreement dated February 22, 2010 (the “Agreement”). All
capitalized terms in the Agreement which are not defined in this First Amendment will have the definitions ascribed to them in the Agreement. 

OSI and Amedica desire to amend the Agreement, as more particularly set forth in this First Amendment. 

The Parties therefore agree as follows: 
  

	 	1.	Incorporation of Recitals. All of the forgoing Recitals are hereby incorporated as agreements of the Parties. 

  

	 	2.	Amendments to the Agreement. OSI and Amedica hereby amend the Agreement as follows: 

  

	 	A.	Section 1(b), in the Definition Section of the Agreement is replaced by the following Section 1(b), which amends, supersedes and replaces Section 1(b) of the Agreement in its entirety: 

 

	 	b.	“Territory” means [***], including the [***]. 

  

	 	B.	Section 2(a), in the Definition Section of the Agreement is replaced by the following Section 2(a), which amends, supersedes and replaces Section 2(a) of the Agreement in its entirety: 

 

	 	2(a)	 Distribution Product Supply. Subject to the terms and conditions of this Agreement, Amedica shall use [***] to
supply OSI with quantities and sizes of the Products as requested by OSI pursuant to written purchase orders. Specifically, Amedica agrees to provide OSI with [***] requested Products before providing [***] to any other
customer of Amedica. Purchase orders shall not be binding 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

	 	
on Amedica until accepted by Amedica and Amedica shall notify OSI promptly in the event that it rejects any purchase order which Amedica may do in the event [***].

  

	 	C.	Section 4(a) of the Agreement is replaced by the following Section 4(a), which amends, supersedes and replaces Section 4(a) of the Agreement in its entirety: 

 

	 	4(a)	Term. The term of this Agreement shall begin upon the Effective Date and expire eight (8) years from regulatory approval or clearance of the Product unless earlier terminated (the “Term”).
The Parties shall be free to mutually agree to any extension or renewal of this Agreement to the extent that same is memorialized in writing and signed by both Parties. 

 

	 	D.	Sections 6(a), 6(b), 6(c) and 6(d) of the Agreement are replaced by the following Section 6(a-d), which amends, supersedes and replaces Sections 6(a), 6(b), 6(c) and 6(d) of the Agreement in their entirety:

  

	 	(a-d)	Pricing: The Parties agree that the pricing of the Products will [***]. 

  

	 	E.	Section 9(b) of the Agreement is replaced by the following Section 9(b), which amends, supersedes and replaces Section 9(b) of the Agreement in its entirety: 

 

	 	9(b)	By OSI. OSI shall defend, indemnify and hold harmless Amedica from and against any claim, liabilities, losses, damages, costs and expenses (including reasonable attorney fees and other costs and expenses)
associated with any claim or action that arises out of or relates to: (i) any [***]; (ii) any claims arising from [***] by OSI or its employees, agents or other representatives; (iii) any failure of OSI, or
its employees, agents or other representatives to comply with any obligation under this Agreement; (iv) any claim that arises out of [***], express, implied or otherwise; (v) any claim arising out of any [***]
by OSI or its employees, agents or other representatives (except to the extent caused by Amedica’s errors or omissions); (vi) any [***] by any party obtaining the Products from OSI or its employees, agents or other
representatives; or (vii) any claim that the OSI Hip System infringes any United States patent, copyright, trademark or trade secret under United States law.  

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

	 	3.	Addendums to the Agreement: OSI and Amedica hereby addend the Agreement as follows: 

  

	 	A.	The following Section, 3(f), is added by Addendum to the Agreement in its entirety: 

  

	 	f.	Regulatory Submission: SiN on Polyethylene 

  

	 	(i)	510(k) Application: The Parties wish to proceed with a 510(k) application (the “510(k)”) for the application of SiN with polyethylene. [***]. 

 

	 	(ii)	Ownership of 510(k). The 510(k) shall be owned by [***] to the extent permitted by law and the regulatory authorities, the rights, responsibilities, obligations with respect to the 510(k).

  

	 	B.	The following Section, 3(g), is added by Addendum to the Agreement in its entirety: 

  

	 	3(g)	Exclusivity Period: Amedica agrees that for a period of [***], which time period shall begin to run upon the Product’s [***] in the [***] (the “Exclusive
License Period”), Amedica shall not [***] or otherwise [***] the SiN technology embodied in each such Product to any third party for use in hip and/or knee systems or components, worldwide. 

 

	 	C.	The following Section, 11(o), is added by Addendum to the Agreement in its entirety: 

  

	 	(o):	Change of Control: In the event of a Change of Control as defined herein, the Parties acknowledge and agree that any successor entity to either Amedica or OSI shall be bound by each and every of the terms
and provisions of this Agreement and that any failure of a successor entity to abide by same shall be considered a material breach of this Agreement. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 For purposes of this Agreement, Change of Control means: 

(i) any public report or notice is filed with any authority in the United States, or any public announcement is made, that discloses
that any person has become the beneficial owner, directly or indirectly, of 50 percent or more of the outstanding voting stock of Amedica or OSI; 

(ii) any person purchases securities pursuant to an offer for cash or exchange of securities to acquire any voting stock of Amedica or
OSI (or any securities convertible into voting stock of Amedica or OSI) and, immediately after consummation of that purchase, that person is the beneficial owner, directly or indirectly, of 50 percent or more of the outstanding voting stock of
Amedica or OSI; 
 (iii) the consummation of 

(a) a merger, stock exchange plan, consolidation or reorganization of Amedica or OSI with or into any other person if as a result of
such merger, stock exchange plan, consolidation or reorganization, less than 50 percent of the combined voting power of the then-outstanding securities of such other person immediately after such merger, consolidation or reorganization are held in
the aggregate by the holders of voting stock of Amedica or OSI immediately prior to such merger, stock exchange plan, consolidation or reorganization; 

(b) any sale, lease, exchange or other transfer of all or substantially all the assets of Amedica or OSI and their respective
consolidated subsidiaries to any other person if as a result of such sale, lease, exchange or other transfer, less than 50 percent of the combined voting power of the then-outstanding securities of such other person immediately after such sale,
lease, exchange or other transfer are held in the aggregate by the holders of voting stock of Amedica or OSI immediately prior to such sale, lease, exchange or other transfer; or 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 (c) a transaction immediately after the consummation of which any person (within the
meaning of Section 13(d) or Section l4(d)(2) of the Exchange Act) would be the beneficial owner (as that term is defined in Rule 13d-3or any successor rule or regulation promulgated under the Exchange Act), directly or indirectly, of more than
50 percent of the outstanding voting stock of Amedica or OSI; or 
  

	 	(iv)	the dissolution of Amedica or OSI is approved in accordance with the laws of the jurisdiction of formation of the respective Party. 

 

	 	4.	No Other Amendments. Except as provided in Section 2 and 3 of this First Amendment, the terms and provisions of the Agreement remain unmodified and in full force and effect. 

 

	 	5.	Counterparts And Facsimile Signatures. This First Amendment may be executed in multiple counterparts, each of which is an original for any and all purposes and all of which together shall constitute one and the
same instrument, and facsimile signatures shall be deemed sufficient to bind either Party hereto. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 IN WITNESS WHEREOF, the Parties have executed this First Amendment as of the Amendment Date. 

 

									
	Orthopaedic Synergy, Inc.	  		 	Amedica Corporation
					
	By:	 	  
	  		 	By:	 	 /s/ Eric K. Olson

	Name:	 		  		 	Name:	 	Eric K. Olson
	Title:	 		  		 	Title:	 	President / CEO

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended.EX-10.30

 Exhibit 10.30 

Execution Version 

TAX SHARING AGREEMENT 

Among and Between 

Cheniere Energy, Inc. 

AND 
 Sabine Pass
Liquefaction, LLC 
 Dated as of August 9, 2012 

 TAX SHARING AGREEMENT 

This Tax Sharing Agreement (the “TSA”) entered into as of the 9th day of August, 2012, to be effective as set forth in
Section 6.1 of this TSA, between Cheniere Energy Inc. (“Cheniere”), a Delaware corporation with its principal office at 700 Milam Street, Suite 800, Houston Texas 77002, and Sabine Pass Liquefaction, LLC
(“Liquefaction”), a Delaware limited liability company, which may be collectively referred to hereinafter as the “Parties” and individually as a “Party.” 

PREAMBLE 
 WHEREAS, the
revised franchise tax imposed by the State of Texas under Chapter 171 of the Texas Tax Code, generally effective for reports due on or after January 1, 2008, requires taxable entities that are part of an affiliated group engaged in a unitary
business to report as a combined group; 
 WHEREAS, Cheniere indirectly owns a controlling interest in Liquefaction within the meaning of
Texas Tax Code §171.0001(8)(C) and expects to file Combined Returns, as required by Texas Tax Code §171.1014, for the combined group that includes Cheniere and Liquefaction; and 

WHEREAS, the Parties believe that the apportionment and allocation of the Texas franchise tax between Cheniere and Liquefaction is desirable.

 NOW, THEREFORE, the Parties to this TSA, for good and valuable consideration, agree as follows: 

ARTICLE I 
 DEFINITIONS

 In addition to any defined terms which may have their meanings ascribed to them elsewhere in this TSA, the following defined terms shall have the
following meanings: 
 “Cheniere” means Cheniere Energy, Inc. and all its subsidiaries and affiliates. 

“Combined Return” means a Texas franchise tax return which reflects combined reporting that includes each of Cheniere’s and
Liquefaction’s reportable separate company Taxable Margin that is required to be apportioned among and between multiple taxing jurisdictions. 

“Combined Return Year” means, with respect to the Texas franchise tax, a period for which Cheniere and Liquefaction are required to file a
Combined Return. 
 “Combined Tax Liability” means, for any Combined Return Year, the Texas franchise tax liability computed in accordance
with Chapter 171 of the Texas Tax Code and reported on Cheniere’s Combined Return, taking into account all credits to which Cheniere is entitled under the Texas franchise tax. 

 “Effective Date” means August 9, 2012. 

“IRS” means the Internal Revenue Service. 

“Liquefaction” means Sabine Pass Liquefaction, LLC. 

“Other Unitary Taxes” means a combined, consolidated, unitary, or similar basis state or local tax other than the Texas franchise tax based
upon or measured by net income, gross margins, gross receipts, or other similar tax attributes on an apportioned basis. 
 “Other Unitary
Return” means a tax return which reflects combined, consolidated or unitary reporting of Cheniere and Liquefaction in respect of Other Unitary Taxes. 

“Pro Forma Separate Company Tax Liability” means, for any tax year, Liquefaction’s separate company Texas franchise tax liability
computed by Liquefaction in accordance with Chapter 171 of the Texas Tax Code prepared on a stand-alone basis that includes only the reportable Taxable Margin of Liquefaction, without regard to any temporary credits provided by Texas Tax Code
§171.111. In arriving at its Pro Forma Separate Company Tax Liability, Liquefaction shall be bound by any tax elections and shall adopt the same tax accounting methods that are elected and adopted by Cheniere in the determination of the
Combined Tax Liability for such period. 
 “Separate Return Year” means, with respect to the Texas franchise tax, a year which is not a
Combined Return Year. 
 “Taxable Margin” has the meaning set forth in Section 171.101 of the Texas Tax Code. 

“Taxing Authority” means, with respect to the Texas franchise tax, the Texas Comptroller of Public Accounts or, with respect to any Other
Unitary Tax, the governmental entity or political subdivision, agency, commission or authority thereof that imposes such Other Unitary Tax, and the agency, commission or authority charged with the assessment, determination or collection of such
Other Unitary Tax for such entity or subdivision. 
 “TSA” means this Tax Sharing Agreement and any attachments, annexes, exhibits,
or amendments hereto. 
 ARTICLE II 

FILING OF COMBINED RETURNS 
 2.1 Filing
of Combined Returns and Payment of Tax. 
 (a) Cheniere shall prepare and timely file all required Combined Returns and such applications
for extension of time to file such Combined Returns and shall timely pay the Combined Tax Liability. Liquefaction agrees to furnish to Cheniere all information as Cheniere 

 
may from time to time reasonably request that is necessary to allow Cheniere to timely file all required Combined Returns. Liquefaction agrees to execute all election forms and other documents
which may be necessary or appropriate to evidence such elections or otherwise as Cheniere may from time to time reasonably request. 
 (b)
Cheniere shall be authorized to and shall undertake the following actions in connection with a Combined Return, including, without limitation: 
  

	 	(i)	taking any and all action necessary or incidental to the preparation and filing of a Combined Return; 

  

	 	(ii)	making all required payments on behalf of Liquefaction for all Combined Return Years; 

  

	 	(iii)	making elections and adopting, modifying and/or revoking accounting methods; provided, however, Cheniere shall not make any elections or adopt, modify or revoke any accounting method that may adversely affect
Liquefaction without Liquefaction’s prior written consent; 

  

	 	(iv)	filing all extensions of time, including extensions of time for payment of tax; 

  

	 	(v)	filing claims for refund or credit; 

  

	 	(vi)	giving waivers or bonds; 

  

	 	(vii)	managing audits and other administrative proceedings conducted by any Taxing Authority; 

  

	 	(viii)	executing closing agreements, settlement agreements, offers in compromise, and all other documents; provided, however, Cheniere shall not enter into any closing agreements, settlement agreements or other similar
agreements that may adversely affect Liquefaction without Liquefaction’s prior written consent; 

  

	 	(ix)	obtaining administrative rulings; and 

  

	 	(x)	contesting (both administratively and judicially) the proposal of adjustments to tax liability and the assessment of any deficiency. 

(c) Cheniere shall determine the tax consequences to Liquefaction of any audits, administrative or judicial proceedings that may affect the
ultimate tax liability of Cheniere; provided, however, Cheniere shall notify Liquefaction upon receipt by Cheniere or its affiliates of notice of any pending or threatened tax audits or assessments relating to any Combined Tax Liability that may
adversely affect Liquefaction’s liability under this TSA. Liquefaction and its representatives shall be permitted, at Liquefaction’s expense, to be present at, and participate in, any such audit or proceeding. 

2.2 Cooperation. 
 (a) Liquefaction agrees
to cooperate with Cheniere in filing any Combined Return or taking any other action contemplated by this TSA and agrees to take such action as Cheniere may reasonably request in connection therewith. 

 (b) The authorization and obligations set forth herein under Article II shall survive the
termination of this TSA with respect to any tax year (or portion thereof) ending on or prior to termination of this TSA. 
 2.3 Standard of Care.

 Cheniere shall perform all duties to be performed by Cheniere under this TSA with skill, diligence and prudence. 

ARTICLE III 
 ALLOCATION
OF TAX LIABILITIES 
 3.1 Allocation of Combined Tax Liability to Liquefaction. 

For Combined Returns first due on or after the effective date of this TSA, and for each subsequent tax year for which this TSA may remain in effect,
Liquefaction, for so long as it is included in a Combined Return, shall calculate and determine its share of the Combined Tax Liability to be an amount equal to the Pro Forma Separate Company Tax Liability. If Liquefaction ceases to be included on a
Combined Return during a tax year, Liquefaction shall calculate and determine its share of the Combined Tax Liability to be that portion of Liquefaction’s separate return tax liability that is allocable to the portion of the tax year in which
Liquefaction was included on a Combined Return. Calculations and determinations in this Article III shall be made by Liquefaction in each tax year pursuant to this paragraph without regard to the actual Combined Tax Liability, if any, of Cheniere
for such year. 
 ARTICLE IV 

PAYMENTS 
 4.1 Payment of Tax by
Liquefaction. 
 If Liquefaction incurs a Pro Forma Separate Company Tax Liability (as determined under Article III), it shall pay to Cheniere an amount
equal to its Pro Forma Separate Company Tax Liability if Cheniere, in its sole discretion, demands such payment. The amount shall be paid by Liquefaction to Cheniere, on or before 45 days after the date for filing, including any extensions granted,
the Combined Return to which such payments relate. 
 4.2 Estimated Combined Tax Payments. 

Notwithstanding Sections 3.1 and 4.1 of this TSA, Cheniere shall have the right to assess Liquefaction its share of estimated Combined Tax Liability with
respect to the projected Pro Forma Separate Company Tax Liability for each Combined Return Year, and Liquefaction shall pay the amount of such assessment to Cheniere within 30 days after such assessment if Cheniere, in its sole discretion, demands
such payment. Cheniere shall not make a demand for payment of 

 
estimated Combined Tax Liability any earlier than 15 days after Cheniere is required to make estimated tax payments of its Combined Tax Liability to the relevant taxing authority. Liquefaction
will receive credit for its payments of estimated Combined Tax Liability in the computation of the payments under Section 3.1 and Section 4.1 of this TSA. 

ARTICLE V 
 ADJUSTMENTS
TO COMBINED TAX LIABILITY 
 5.1 Recomputations. 

If a Combined Tax Liability is adjusted for any taxable period, whether such adjustment is by means of an amended return, claim for refund, examination by the
IRS or Taxing Authority, reduced to settlement or otherwise determined or otherwise, the calculations made under this TSA shall be recomputed by giving effect to such adjustments. In all cases the recomputations required by the preceding sentence
shall be performed consistently with the definition of “Combined Tax Liability.” Cheniere shall pay to Liquefaction, not later than 30 days after the date of recomputation, the excess, if any, of Liquefaction’s payments of estimated
Combined Tax Liability made to Cheniere for such taxable year over Liquefaction’s recomputed Pro Forma Separate Company Tax Liability. 
 5.2
Liquefaction’s Additional Tax Liability. 
 If, following such recomputation, the parties determine that Liquefaction is liable for additional
payments under this TSA, Liquefaction shall be obligated to pay to Cheniere such additional amount within ninety (90) days after the earlier of either of the following events which relate to such recomputation: (i) Cheniere files an
amended Combined Return; or (ii) Cheniere settles an examination with the IRS or another Taxing Authority. 
 5.3 Interest and Penalties. 

Any interest and/or penalty not specifically allocated to Liquefaction by the Taxing Authority may be allocated to Liquefaction upon such basis as Cheniere and
Liquefaction deem appropriate in view of all applicable circumstances. 
 ARTICLE VI 

MISCELLANEOUS 
 6.1 Term of this
Agreement. 
 This TSA is effective for the Texas franchise tax return first due on or after the effective date of this TSA, and all subsequent years. As
such, this TSA shall apply to all taxable years or portions thereof for which a Combined Return was or is filed with respect to Liquefaction that was included as part of such return(s), unless Cheniere and Liquefaction agree in writing to another
arrangement or otherwise agree to terminate this TSA. Notwithstanding any other provision herein, if Liquefaction generates net operating losses, net capital losses, or credits against taxes that will be utilized (i) to reduce the Combined Tax
Liability as a result of any alteration, 

 
modification, addition, deletion or other change in the Texas Tax Code or regulations relating to the Texas franchise tax or (ii) to reduce the consolidated, combined or unitary group’s
Other Unitary Taxes, if any, with respect to which Cheniere is permitted or required to file an Other Unitary Return with Liquefaction on a consolidated, combined or unitary basis, the Parties shall negotiate in good faith to amend this TSA in a way
that would result in a fair and equitable sharing of the tax benefits from such attributes between the Parties as a result of such change in law or circumstances. Notwithstanding any termination, this TSA shall continue in effect with respect to any
payment or refund due for all taxable periods prior to termination. 
 6.2 Assignability. 

The rights and obligations under this TSA of the Parties may not be assigned or otherwise transferred by a Party without the prior written and unanimous
consent of all other signatories to this TSA, provided, however, no consent from any other Party shall be required with respect to any assignment and transfer to Cheniere. 

6.3 Effect of Changes to the Texas Tax Code. 
 Any
alteration, modification, addition, deletion, or other change in the federal income tax laws or regulations or the Texas Tax Code or regulations relating to Texas franchise tax shall automatically be applicable to this TSA, provided, however, that
if all the Parties to this TSA unanimously agree, this TSA shall be amended or terminated in the event of any such alteration, modification, addition, deletion or other change. 

6.4 Other Unitary Taxes. 
 To the extent Cheniere is
permitted or required to file an Other Unitary Return with Liquefaction on a consolidated, combined or unitary basis, the provisions of this TSA relating to Texas franchise tax matters shall apply to such Other Unitary Taxes as if they were Texas
franchise taxes. If such an Other Unitary Return with respect to Other Unitary Taxes is not filed, the responsible party as required by applicable law shall be responsible for the reporting and payment of any Other Unitary Taxes applicable to such
party. 
 6.5 Record Retention. 
 Liquefaction shall
make available to Cheniere all materials (including, without limitation, all books and records, accounting information, financial statements, returns, supporting schedules, work papers, correspondence, and other documents) relating to the Combined
Returns filed for the taxable years during which this TSA was in effect during regular business hours for a period that is not less than the applicable federal record retention requirement period. 

6.6 Binding Effect. 
 This TSA shall be binding upon and
inure to the benefit of the respective successors and assigns of the Parties hereto; but no assignment shall relieve any Party’s obligations hereunder without the written consent of the other Parties. In the event that Liquefaction is no longer
required to be included on a Combined Return with Cheniere, it shall be bound, nevertheless, by this TSA with respect to any matter that involves a taxable year (or portion thereof) during which it was included in a Combined Return. 

 6.7 Waivers, Etc. 

The terms of this TSA may be waived, altered or amended only by an instrument in writing duly executed by all of the Parties. Any such amendment or waiver
shall be binding upon all of the Parties. 
 6.8 Severability. 

If any provision hereof is invalid and unenforceable in any jurisdiction, then, to the fullest extent permitted by law: 

(a) the other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in favor of the
Parties in order to carry out the intentions of the Parties hereto as nearly as may be possible; and 
 (b) the invalidity or
unenforceability of any provision hereof in any jurisdiction shall not affect the validity or enforceability of such provision in any other jurisdiction. 

6.9 WAIVER OF JURY TRIAL. 
 THE PARTIES HEREBY IRREVOCABLY
WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 

6.10 Governing Law. 
 This TSA shall be governed by the
laws of the State of Delaware. 

 IN WITNESS THEREOF, the Parties hereto have caused their names to be subscribed and executed by their respective
authorized officers as indicated. 
  

			
	Cheniere Energy, Inc.
		
	By:	 	 /s/ Meg A. Gentle

	Name: Meg A. Gentle
	Title:   Senior Vice President and
		 	     Chief Financial Officer
	
	Sabine Pass Liquefaction, LLC
		
	By:	 	 /s/ R. Keith Teague

	Name: R. Keith Teague
	Title:   President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]